To wipe out global poverty, transfer money to the people who work hardest to earn it
Law firms are suffering in many areas, but patent infringement cases are flourishing
Half of U.S. renters spend at least 30 percent of their income on rent, with more than 11 million of them paying at least half of it and cutting back on food consumption
After crushing a Samwer brothers' clone attempt, online retail startup Fab expanded aggressively—right into a wave of layoffs
Hedge fund manager John Paulson has reversed dramatic losses with strong results for 2013, far outstripping hedge rivals' meager gains in a strong market
Sriracha is no longer a mere condiment—food manufacturers gigantic and small have turned the spicy, sweet, garlicky, hot sauce into a marketing flavor
After breaking up with Disney, he wants to produce sequels to Beverly Hills Cop and Top Gun
Northwestern's Kellogg School of Management reclaims the top stop after a two-year absence
Immigrant entrepreneurs and companies with intellectual property are more likely to hire
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.